UniCAR02-T-pPSMA

BIOLOGICAL2 trials

Sponsors

AvenCell Europe GmbH, AvenCell Therapeutics, Inc.

Conditions

AML (Acute Myelogenous Leukemia)B-cell LymphomaChronic Lymphocytic LeukemiaHematologic MalignancyProstate Cancer

Phase 1

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

TerminatedNCT04633148

AvenCell Europe GmbHProstate Cancer

Start: 2020-11-23End: 2024-03-28Updated: 2024-04-23

Unknown Phase

Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials

Enrolling by invitationNCT07474051

AvenCell Therapeutics, Inc.AML (Acute Myelogenous Leukemia), B-cell Lymphoma, Chronic Lymphocytic Leukemia +2

Start: 2026-01-29End: 2041-01-30Target: 178Updated: 2026-03-16